# A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

> **NCT02116582** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 215 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02116582
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-23
- **Primary completion:** 2016-05-08
- **Final completion:** 2017-09-29
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116582, "A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02116582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*